Korea to back 200 pharma, biotech and medtech firms through 2030 < Policy < Article



The Korean government plans to support 200 promising pharmaceutical, biotech, medical device and digital health companies through 2030, offering up to five years of assistance and a combined 150 billion won ($112 million) in planned investment and financing guarantees.


The Ministry of Health and Welfare (MOHW) and the Ministry of SMEs and Startups (MSS) announced the K-Pharma Bio Frontier initiative Thursday, aiming to help small and medium-sized companies overcome funding and commercialization barriers.


Korea's health and startup ministries plan to support 200 pharmaceutical, biotech, medical device and digital health companies through 2030. (Getty Images)
Korea’s health and startup ministries plan to support 200 pharmaceutical, biotech, medical device and digital health companies through 2030. (Getty Images)


The initiative comes as Korea’s pharmaceutical and biotech market continues to grow, reaching 31.7 trillion won in 2024 from 23.2 trillion won in 2020. However, the number of new biotech ventures fell from 581 in 2020 to 288 in 2023, reflecting difficult investment conditions for early-stage companies.


Under the plan, the ministries will jointly select 50 companies annually, including 20 in drug development, 20 in medical devices and digital health, and 10 in biomaterials and production technologies.


Selected companies will receive two years of tailored support for R&D, clinical development and commercialization, along with guidance from dedicated advisers. Those meeting performance targets may qualify for another three years of assistance, including investment and overseas expansion support.


The government also plans to provide 60 billion won in investment over three years through designated banks and 90 billion won in guarantees for commercialization.


The initiative will support AI-based drug discovery, access to medical and biological data, and research into alternatives to animal testing, including organoids and organ-on-a-chip technologies.


The ministries will also help commercialize research from hospitals and universities, connect startups with global pharmaceutical companies for joint R&D and investment, and support overseas expansion through international networks and facilities in Chicago and Texas.


Minister of Health and Welfare Jeong Eun-kyeong said the government would combine the health ministry’s clinical infrastructure and industry expertise with the startup ministry’s business development capabilities to help Korean companies compete globally.


Minister of SMEs and Startups Lee So-young said the initiative would provide continuous support to prevent promising companies from being held back by funding shortages and commercialization barriers.

Leave a Reply

Your email address will not be published. Required fields are marked *